HTB

CROI 2019 (Retrovirus)

Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019

INSTI and weight gain: reports from CROI 2019

B/F/TAF suitable for children from six years of age

Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports

Paediatric dolutegravir update

Other cure related studies at CROI 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

Capsid inhibitor GS-6297 shows potential for 3-monthly injections

First phase 1 results from bNAb PGT121 in HIV positive people

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

Same-day ART is effective in San Francisco Rapid-ART clinic

Integrase inhibitors and neural tube defects: more data still needed

Double-dose levonorgestrel implant does not overcome interaction with efavirenz

Efavirenz and rifampicin together reduce levels of injectable contraception

Bedaquiline and delamanid safe when given together to treat drug resistant TB

Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes

Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports

UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants

Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies

Viral reservoir can explain persistent low level viraemia with good adherence on ART

Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study

Dolutegravir can be given with 3HP to prevent TB without dose adjustment

Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques

Selected webcasts at CROI 2019

i-Base Fit for Purpose report launched at CROI 2019

Pre-CROI Community HIV Cure Workshop 2019